Charles Schwab
KYMR icon

Charles Schwab’s Kymera Therapeutics KYMR Stock Holding History

Charles Schwab’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.7M Buy
529,729
+34,467
+7% +$2.96M 0.01% 1112
2026
Q1 		$41.3M Sell
495,262
-1,764
-0.4% -$140K 0.01% 1278
2025
Q4 		$38.7M Buy
497,026
+57,201
+13% +$3.86M 0.01% 1319
2025
Q3 		$24.9M Buy
439,825
+10,521
+2% +$475K ﹤0.01% 1612
2025
Q2 		$18.7M Buy
429,304
+47,596
+12% +$1.64M ﹤0.01% 1711
2025
Q1 		$10.4M Sell
381,708
-5,479
-1% -$200K ﹤0.01% 1932
2024
Q4 		$15.6M Buy
387,187
+20,346
+6% +$919K ﹤0.01% 1822
2024
Q3 		$17.4M Sell
366,841
-8,260
-2% -$365K ﹤0.01% 1773
2024
Q2 		$11.2M Buy
375,101
+20,995
+6% +$727K ﹤0.01% 1992
2024
Q1 		$14.2M Buy
354,106
+47,414
+15% +$1.7M ﹤0.01% 1810
2023
Q4 		$7.81M Buy
306,692
+4,951
+2% +$88.5K ﹤0.01% 2121
2023
Q3 		$4.19M Buy
301,741
+639
+0.2% +$12.8K ﹤0.01% 2334
2023
Q2 		$6.92M Buy
301,102
+2,605
+0.9% +$74.6K ﹤0.01% 2082
2023
Q1 		$8.84M Buy
298,497
+589
+0.2% +$19K ﹤0.01% 1930
2022
Q4 		$7.44M Buy
297,908
+19,348
+7% +$516K ﹤0.01% 2009
2022
Q3 		$6.07M Buy
278,560
+22,018
+9% +$580K ﹤0.01% 2117
2022
Q2 		$5.05M Buy
256,542
+1,265
+0.5% +$29.5K ﹤0.01% 2182
2022
Q1 		$10.8M Buy
255,277
+6,743
+3% +$285K ﹤0.01% 1915
2021
Q4 		$15.8M Buy
248,534
+5,309
+2% +$309K ﹤0.01% 1752
2021
Q3 		$14.3M Buy
243,225
+139,149
+134% +$8.07M ﹤0.01% 1811
2021
Q2 		$5.05M Buy
104,076
+41,628
+67% +$1.81M ﹤0.01% 2353
2021
Q1 		$2.43M Buy
62,448
+1,114
+2% +$67.1K ﹤0.01% 2608
2020
Q4 		$3.8M Buy
+61,334
New +$2.99M ﹤0.01% 2350

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Charles Schwab's KYMR Position: Q2 2026 in Review

Charles Schwab increased its Kymera Therapeutics (KYMR) stake by 7% in Q2 2026, buying an estimated $2.96M and bringing the position to 529,729 shares worth $60.7M. The position accounts for 0.01% of the portfolio, ranked #1112.

Charles Schwab first reported a position in KYMR in Q4 2020 and has held it in 23 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Charles Schwab held 529,729 shares of Kymera Therapeutics worth $60.7M as of Q2 2026.
  • Charles Schwab bought 34,467 Kymera Therapeutics shares in Q2 2026, an estimated $2.96M.
  • Kymera Therapeutics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1112 holding.
  • Charles Schwab first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.